补中益气颗粒联合曲美布汀治疗脾胃虚弱证腹泻型肠易激综合征的疗效观察

目的观察补中益气颗粒联合曲美布汀治疗脾胃虚弱证腹泻型肠易激综合征的临床疗效。方法选取2015年6月—2016年5月在天津中医药大学第一附属医院脾胃科门诊就诊的脾胃虚弱证腹泻型肠易激综合征患者60例,每组各30例。对照组患者口服马来酸曲美布汀片,0.2 g/次,3次/d。治疗组在对照组的基础上口服补中益气颗粒,3 g/次,3次/d。两组患者均连续治疗4周。观察两组患者临床疗效,比较治疗前后两组症状积分、排便情况和焦虑抑郁症状评分的变化。结果治疗后,对照组和治疗组的总有效率分别为83.33%和96.67%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者腹泻、腹痛、腹胀积分均较治疗前明显下降(P0.01);且治疗组低于对照组(P0.01)。治疗后,两组患者日排便次数及10 d内排便急迫天数均较治疗前降低(P0.05);且治疗后治疗组优于对照组(P0.05)。治疗后,两组SAS评分、SDS评分均较治疗前显著降低(P0.05);且治疗后治疗组SAS和SDS评分优于对照组(P0.05)。结论补中益气颗粒联合曲美布汀对脾胃虚弱证腹泻型肠易激综合征疗效确切,具有一定的临床推广应用价值。

Clinical observation of Buzhong Yiqi Granules combined with trimebutine in treatment of irritable bowel syndrome of diarrhea type with spleen and stomach deficiency

Objective To observe the clinical efficacy of Buzhong Yiqi Granules combined with trimebutine in treatment of irritable bowel syndrome of diarrhea type with spleen and stomach deficiency. Methods Patients (60 cases) with irritable bowel syndrome of diarrhea type with spleen and stomach deficiency in First Teaching Hospital of Tianjin University of TCM from June 2015 to May 2016 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Trimebutine Maleate Tablets, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Buzhong Yiqi Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and symptom scores, defecation, SAS and SDS scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 96.67% respectively, and there was difference between two groups (P<0.05). After treatment, the diarrhea, abdominal pain, abdominal distension scores in two groups were significantly decreased (P<0.01). And the symptom scores of the treatment group were significantly lower than those in the control group (P<0.01). After treatment, the daily defecation frequency and days of defecation urgency in 10 d in two groups were significantly decreased (P<0.05). And those indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the SAS and SDS scores in two groups were significantly decreased (P<0.05). The SAS and SDS scores in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Buzhong Yiqi Granules combined with trimebutine has a reliable clinical curative effect in treatment of irritable bowel syndrome of diarrhea type with spleen and stomach deficiency, which has a certain clinical application value.